Quality of life in long-term survivors of oropharynx carcinoma

被引:76
作者
Pourel, N
Peiffert, D
Lartigau, E
Desandes, E
Luporsi, E
Conroy, T
机构
[1] Ctr Alexis Vautrin, Dept Radiat Oncol, Vandoeuvre Les Nancy, France
[2] Ctr Alexis Vautrin, Dept Clin Res, Vandoeuvre Les Nancy, France
[3] Ctr Oscar Lambret, Dept Radiat Oncol, F-59020 Lille, France
[4] Upres, Sch Publ Hlth, Nancy, France
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2002年 / 54卷 / 03期
关键词
head-and-neck cancer; oropharynx; treatment; quality of life; long-term survivors; EORTC QLQ-C30;
D O I
10.1016/S0360-3016(02)02959-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To collect data on the health-related quality of life (QOL) of long-term survivors and to determine to what extent QOL might be an appropriate end point in the comparison of treatment options in oropharyngeal carcinoma. Methods and Materials: All patients treated between 1992 and 1998, in two French comprehensive cancer centers, by brachytherapy (BT) +/- external beam radiotherapy (EBRT) or surgery plus RT, or exclusive EBRT for T1-T3 (International Union Against Cancer staging system) oropharynx squamous cell carcinoma, were included. QOL was measured once in disease-free patients at least 2 years after treatment initiation. The European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire and the specific H&N35 module were self-administered by all participating patients. Sociodemographic data were collected using a questionnaire specifically designed for the study. The association between the QOL scores of the various treatment-, disease-, and patient-related variables was performed through bivariate analysis and then by multivariate analysis. The mean QOL scores of the EORTC QLQ-C30 questionnaire were compared with the mean scores in the general population. Results: Of the 159 eligible patients, 113 agreed to participate (97 men and 16 women, median age 61 years, range 41-83). The initial treatment was EBRT plus BT in 49 patients, surgery plus RT in 27, and EBRT alone in 37. The median follow-up time was 62 months (range 24-110). Compared with the general population, the three scores indicating the most impaired QOL were emotional and social functioning and fatigue. The clinical significance of global QOL impairment was borderline. The physical functioning, role functioning, and pain scores did not significantly differ from those of the general population. In multivariate analysis, the initial treatment had no significant influence on any dimension of QOL, except global QOL and emotional functioning. Surprisingly, surgery plus RT, as the initial treatment, favorably influenced the emotional functioning score and EBRT plus BT negatively influenced the global QOL score. None of these treatment modalities influenced any symptom scales. Patient selection was, at least partially, responsible for these paradoxical results. Conclusion: The results of this study bring original and useful data about the QOL of long-term survivors of oropharynx carcinoma. In these patients, the QOL was significantly impaired, particularly in its psychosocial dimensions. The level of symptoms and functioning (except global QOL and emotional) was similar whatever the initial treatment. These results suggest the importance of coping processes. In a trial comparing treatment options from a long-term perspective, survival remains the most relevant end point, and a QOL evaluation should be a secondary end point. More prospective studies on QOL in head-and-neck cancer patients are needed to determine new strategies for rehabilitation management. (C) 2002 Elsevier Science Inc.
引用
收藏
页码:742 / 751
页数:10
相关论文
共 43 条
[1]  
Aaronson N K, 1992, Qual Life Res, V1, P349, DOI 10.1007/BF00434949
[2]   THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY [J].
AARONSON, NK ;
AHMEDZAI, S ;
BERGMAN, B ;
BULLINGER, M ;
CULL, A ;
DUEZ, NJ ;
FILIBERTI, A ;
FLECHTNER, H ;
FLEISHMAN, SB ;
DEHAES, JCJM ;
KAASA, S ;
KLEE, M ;
OSOBA, D ;
RAZAVI, D ;
ROFE, PB ;
SCHRAUB, S ;
SNEEUW, K ;
SULLIVAN, M ;
TAKEDA, F .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :365-376
[3]   Correlates of health-related quality of life in upper aerodigestive tract cancer patients [J].
Allison, PJ ;
Locker, D ;
Wood-Dauphinee, S ;
Black, M ;
Feine, JS .
QUALITY OF LIFE RESEARCH, 1998, 7 (08) :713-722
[4]   Quality of life in head and neck cancer patients:: Validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire -: H&N35 [J].
Bjordal, K ;
Hammerlid, E ;
Ahlner-Elmqvist, M ;
de Graeff, A ;
Boysen, M ;
Evensen, JF ;
Biörklund, A ;
de Leeuw, JRJ ;
Fayers, PM ;
Jannert, M ;
Westin, T ;
Kaasa, S .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (03) :1008-1019
[5]   PSYCHOLOGICAL DISTRESS IN HEAD-AND-NECK-CANCER PATIENTS 7-11 YEARS AFTER CURATIVE TREATMENT [J].
BJORDAL, K ;
KAASA, S .
BRITISH JOURNAL OF CANCER, 1995, 71 (03) :592-597
[6]   PATIENT SELF-REPORTED AND CLINICIAN-RATED QUALITY-OF-LIFE IN HEAD AND NECK-CANCER PATIENTS - A CROSS-SECTIONAL STUDY [J].
BJORDAL, K ;
FRENG, A ;
THORVIK, J ;
KAASA, S .
ORAL ONCOLOGY-EUROPEAN JOURNAL OF CANCER PART B, 1995, 31B (04) :235-241
[7]   A prospective study on quality of life of patients with cancer of the oral cavity or oropharynx treated with surgery with or without radiotherapy [J].
de Graeff, A ;
de Leeuw, JRJ ;
Ros, WJG ;
Hordijk, GJ ;
Blijham, GH ;
Winnubst, JAM .
ORAL ONCOLOGY, 1999, 35 (01) :27-32
[8]   Long-term quality of life of patients with head and neck cancer [J].
de Graeff, A ;
de Leeuw, JRJ ;
Ros, WJG ;
Hordijk, GJ ;
Blijham, GH ;
Winnubst, JAM .
LARYNGOSCOPE, 2000, 110 (01) :98-106
[9]   REHABILITATION OUTCOMES OF LONG-TERM SURVIVORS TREATED FOR HEAD AND NECK-CANCER [J].
DEBOER, MF ;
PRUYN, JFA ;
VANDENBORNE, B ;
KNEGT, PP ;
RYCKMAN, RM ;
VERWOERD, CDA .
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 1995, 17 (06) :503-515
[10]  
Deleyiannis FWB, 1997, HEAD NECK-J SCI SPEC, V19, P466, DOI 10.1002/(SICI)1097-0347(199709)19:6<466::AID-HED2>3.0.CO